Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term follow-up and booster evaluation of Takeda tetravalent dengue vaccine in healthy adolescents and adults
2023-000027-36Phase 3
- Sponsor
- Takeda
- Start
- Feb 2023
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3 trial of dengue tetravalent vaccine, live, attenuated in dengue fever (2 arms), sponsored by Takeda. Primary endpoint: Geometric Mean Titers of neutralizing antibodies for each of the 4 dengue serotypes prior to booster dose.
02
Drugs
dengue tetravalent vaccine, live, attenuated
03
Conditions
dengue fever
Beyond the preview
Go deeper on 2023-000027-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-000027-36.